Powder: -20°C for 3 years | In solvent: -80°C for 1 year
IDO1/TDO-IN-4 displays potent inhibition of both IDO1 (IC50 = 3.53 μM) and TDO (IC50 = 1.15 μM) and has an acceptable safety profile and pharmacokinetic properties. IDO1/TDO-IN-4 forms a hydrogen bond with IDO1, and π π stacking interaction with TDO. IDO1/TDO-IN-4 can be used in the research of depression and inflammation-induced depression [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | 5 days | $ 59.00 | |
5 mg | 5 days | $ 128.00 |
Description | IDO1/TDO-IN-4 displays potent inhibition of both IDO1 (IC50 = 3.53 μM) and TDO (IC50 = 1.15 μM) and has an acceptable safety profile and pharmacokinetic properties. IDO1/TDO-IN-4 forms a hydrogen bond with IDO1, and π π stacking interaction with TDO. IDO1/TDO-IN-4 can be used in the research of depression and inflammation-induced depression [1]. |
In vitro | IDO1/TDO-IN-4 (compound 28, 0-2 µM, 1 h) effectively suppresses the activation of LPS-induced BV2 microglial cells, evident through changes in morphology, and impairs the production of pro-inflammatory agents while enhancing IL-10 expression. Additionally, this compound diminishes IDO1 expression, thus blocking the excessive breakdown of tryptophan through the kynurenine pathway. RT-PCR analysis demonstrates that, at concentrations ranging from 0 to 2 µM and an incubation time of 1 hour, IDO1/TDO-IN-4 curtails the synthesis of COX2, iNOS, TNF-α, and IL-1β, and concurrently, elevates IL-10 levels in 100 ng/mL LPS-stimulated BV2 microglial cells. |
In vivo | IDO1/TDO-IN-4, also known as compound 28, administered at 20 mg/kg intraperitoneally on days 1, 2, and 3, effectively mitigates LPS-induced neuroinflammation and depressive-like behavior in mice, demonstrating significant reduction in microglial activation and inflammatory markers (TNF-α, IL-1β, and iNOS) within the hippocampus, and suppressing the LPS-induced upregulation of IDO1. In pharmacokinetic assessments in male C57BL/6J mice, IDO1/TDO-IN-4, regardless of being administered intraperitoneally or intravenously, showed high exposure and volume of distribution at steady state, with notable pharmacokinetic parameters including a half-life (T 1/2) of 2.31 hours (i.v.) and 0.77 hours (i.p.), maximum concentration (C max) of 5543.99 ng/mL (i.v.) and 3878 ng/mL (i.p.), and a bioavailability (F %) of 52.55. |
Molecular Weight | 234.26 |
Formula | C14H10N4 |
CAS No. | 461424-21-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
IDO1/TDO-IN-4 461424-21-5 inhibitor inhibit